SRRK: Apitegromab nears FDA approval with robust demand, global expansion, and a strong market position

Apitegromab is poised for FDA approval following strong phase III results and a successful switch to a compliant manufacturing facility. Demand is high across SMA patient groups, with broad label expectations and global expansion plans, especially in Japan and Europe.Based on Scholar Rock Holding C…